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Two hundred twelve patients with colonization/infection due to amoxicillin-clavulanate (AMC)-resistant Escherichia coli were
studied. OXA-1- and inhibitor-resistant TEM (IRT)-producing strains were associated with urinary tract infections, while
OXA-1 producers and chromosomal AmpC hyperproducers were associated with bacteremic infections. AMC resistance in E.
coli is a complex phenomenon with heterogeneous clinical implications.
Amoxicillin-clavulanate (AMC) is one of the most frequentlyused antimicrobials in many countries (1, 2). Over the last
years, an increase in the rate of resistance to AMC has been noted
among Escherichia coli isolates in several areas (3–5), which has
been related to an increase in the consumption of this antibiotic
(3). However, to our knowledge, there are no recent clinical stud-
ies investigating infections caused by AMC-resistant E. coli. The
objective of this study is to analyze the clinical epidemiology and
features of infections caused by AMC-resistant E. coli.
A cross-sectional multicenter study was performed in 7 Span-
ish tertiary centers. Each center was committed to include up to 44
patients from whom AMC-resistant E. coli (MIC of32 [amoxi-
cillin]-16 [clavulanate] mg/liter and/or disk inhibition zone of
13 mm) were isolated from clinical samples (22 community-
onset and 22 nosocomial isolates) from 15 January to 15 May
2010. Overall, 257 AMC-resistant E. coli isolates were collected. A
previous publication reported the mechanism of resistance to
AMC and clonality for all these isolates (6). For the present anal-
ysis, 13 patients harboring isolates with more than one mecha-
nism of resistance to AMC, 3 patients harboring isolates for which
the mechanism of resistance was not elucidated, and 37 patients
with isolates producing extended-spectrum-lactamases (ESBLs)
were excluded; thus, 212 patients are studied here. Epidemiolog-
ical and clinical data were collected by reviewing the clinical charts
and interviewing the patients or their relatives. The study was
approved by the ethics committees of the participating centers.
Isolates were considered nosocomial if obtained from patients
who were hospitalized for48 h. Community isolates were clas-
sified as health care associated according to previously described
criteria (7). CDC criteria (8) were used for establishing whether
the patients had an infection and the types of infection.
The microbiological methods used were previously reported in
detail (6). Briefly, antibiotic susceptibility was confirmed by mi-
crodilution according to CLSI recommendations (9). The mech-
anisms of resistance to AMC of the 212 isolates included here, as
determined from the previously reported data (6), were as follows:
hyperproduction of TEM-1 or SHV-1 (HPen) (54 isolates
[25.5%]), production of inhibitor-resistant TEM (IRT) (43
[20.3%]), hyperproduction of chromosomal AmpC (c-AmpC)
(40 [18.9%]), production of plasmidic AmpC (p-AmpC) (40
[18.9%]), and production of OXA-1 (35 [16.5%]). Isolates show-
ing resistance to at least one of the following families/drugs (in
addition to AMC and ampicillin) were considered multidrug re-
sistant: aminoglycosides, cephalosporins, carbapenems, piperacil-
lin-tazobactam, ciprofloxacin, and trimethoprim-sulfamethoxa-
zole (10). The number of above-mentioned families/drugs to
which each isolate was not susceptible (resistance score) was cal-
culated. Proportions with 95% confidence intervals (CIs) were
used to compare categorical variables. Multivariate analyses were
performed by logistic regression analysis; variables were selected
by a stepwise backward method.
The microbiological features of the 212 isolates included are
shown in Table S1 in the supplemental material. c-AmpC hyper-
producers and OXA-1 producers belonged more frequently to
phylogroup A1, while HPen, IRT, and p-AmpC producers more
frequently belonged to phylogroup B2. HPen and OXA-1 produc-
ers were less susceptible to piperacillin-tazobactam; OXA-1-pro-
ducers were also less susceptible to ciprofloxacin, gentamicin, to-
bramycin, and trimethoprim-sulfamethoxazole; and c-AmpC
hyperproducers and p-AmpC producers were less susceptible to
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cefotaxime and ceftazidime. IRT producers were less frequently
multidrug resistant.
Data for exposure to predisposing factors are shown in Table 1.
Nosocomial acquisition and previous exposure to piperacillin-
tazobactam were more frequent among HPen isolates. When the
susceptibility of the specific isolate to the previously used antimi-
crobial in each patient was considered, a significant association
was found for piperacillin-tazobactam (a resistant strain was iso-
lated in 14/20 [70%] patients exposed to this antimicrobial, versus
39/192 [35.9%] patients not exposed; relative risk [RR]  1.96;
95% CI, 1.38 to 2.74; P 0.003) and ciprofloxacin (30/41 [73.2%]
versus 82/171 [48%]; RR 1.52; 95% CI, 1.19 to 1.94; P 0.004)
but not for other antimicrobials (data not shown).
The types of infections are shown in Table 2. Urinary tract
infections (UTIs) and specifically cystitis were somehow more fre-
quent among IRT and OXA-1 producers, particularly in compar-
ison to HPen. On the contrary, skin and soft tissue infections were
more frequent among HPen isolates. We further investigated
whether some specific mechanism of resistance was indepen-
dently associated with urinary tract infection as opposed to other
infections and to the occurrence of bacteremia by using logistic
regression analysis. The final models are shown in Table S2 in the
supplemental material. In summary, IRT and OXA-1 producers of
the B2 phylogroup were associated with UTI, and c-AmpC hyper-
producers and OXA-1 producers were associated with bacteremic
infections. Among bacteremic infections, all 4 caused by OXA-1
producers and 2 out of the 6 caused by c-AmpC hyperproducers
belonged to phylogroup A.
These data, together with those focused on the molecular as-
pects previously reported (6), show that AMC resistance in E. coli
is a complex and heterogeneous phenomenon from both molec-
ular and clinical points of view. We hypothesize that the recent
increase in AMC consumption triggered the spread of diverse
mechanisms of resistance that were initially limited to some iso-
lates or clones in specific epidemiological niches.
The epidemiologic features of the patients infected with AMC-
resistant isolates were somehow similar to those found among
patients harboring ESBL-producing or p-AmpC-producing E. coli
(7, 11); a more specific finding is the frequent previous exposure
to -lactam–-lactam inhibitors, particularly AMC. Of note, pa-
tients with HPen isolates were significantly more frequently ex-
posed to piperacillin-tazobactam, in relation with the fact that
HPen isolates were also more frequently resistant to this antimi-
crobial (patients with OXA-1-producing isolates, which were also
frequently resistant, were less exposed to this antimicrobial be-
cause of a predominance of nonnosocomial infections). Previous
use of fluoroquinolones was associated with isolation of a strain
resistant to these drugs; this is another example of the strong co-
selection activity of fluoroquinolones (12).
Regarding the differences across the specific AMC-related
mechanisms of resistance, OXA-1-producing isolates were mostly
from phylogroup A and showed the highest resistance score but,
TABLE 1 Exposure to predisposing factors among amoxicillin-clavulanate-resistant E. coli isolates according to mechanism of resistancea
Predisposing factor
% of patients (95% CI) harboring isolate with mechanism of resistance
All cases (n 212) HPen (n 54) c-AmpC (n 40) p-AmpC (n 40) IRT (n 43) OXA-1 (n 35)
Male gender 33 (27–40) 35 (24–48) 22 (12–37) 35 (22–50) 30 (19–45) 43 (28–59)
Age65 yr 52 (45–58) 41 (29–54) 22 (12–37) 22 (12–37) 42 (28–57) 68 (52–81)
Type of acquisition
Nosocomial 42 (35–49) 63 (50–74) 30 (18–45) 45 (31–60) 32 (20–47) 31 (18–48)
Health care related 24 (18–30) 9 (4–20) 30 (18–45) 32 (20–48) 30 (19–45) 20 (10–36)
Community 34 (28–41) 28 (18–41) 40 (26–55) 22 (12–37) 37 (24–52) 48 (33–64)
Nursing home resident 7 (4–11) 2 (0–10) 10 (4–23) 12 (5–26) 7 (2–19) 3 (0–14)
Diabetes mellitus 19 (14–25) 22 (13–25) 27 (16–43) 12 (5–26) 16 (8–20) 14 (6–29)
Chronic pulmonary disease 10 (7–15) 17 (9–29) 12 (5–26) 2 (0–13) 9 (4–22) 8 (3–22)
Chronic renal insufficiency 12 (8–17) 13 (6–24) 10 (4–23) 12 (5–26) 12 (5–24) 14 (6–29)
Chronic liver disease 6 (3–10) 7 (3–17) 5 (1–16) 5 (1–16) 9 (4–22) 0 (0–10)
Malignancy 19 (14–25) 22 (13–25) 10 (4–23) 20 (10–35) 14 (6–27) 28 (16–45)
Urinary catheter 20 (15–26) 30 (19–43) 17 (9–32) 27 (16–43) 9 (4–22) 14 (6–29)
Previous antibiotic use 58 (52–65) 61 (48–73) 60 (45–74) 67 (52–80) 58 (43–72) 43 (28–59)
Amoxicillin-clavulanate 26 (21–33) 28 (18–41) 30 (18–45) 22 (12–37) 35 (22–50) 14 (6–29)
Piperacillin-tazobactam 9 (6–14) 28 (18–41) 2 (0–13) 0 (0–9) 16 (8–20) 3 (0–14)
Carbapenems 8 (5–12) 11 (5–22) 5 (1–16) 10 (4–23) 16 (8–20) 6 (1–19)
Cephalosporins 7 (5–12) 7 (3–17) 0 (0–9) 10 (4–23) 12 (5–24) 8 (3–22)
Fluoroquinolones 19 (15–25) 17 (9–29) 20 (10–35) 22 (12–37) 19 (10–33) 20 (10–36)
Aminoglycosides 4 (2–7) 6 (2–15) 2 (0–13) 2 (0–13) 7 (2–19) 0 (0–10)
a HPen, TEM-1 or SHV-1 hyperproducer; IRT, inhibitor-resistant TEM producer; c-AmpC, chromosomal AmpC hyperproducer; p-AmpC, plasmidic AmpC producer; OXA-1,
OXA-1 producer.
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unexpectedly, were associated with both UTI and bacteremic in-
fections. We recently showed that phylogroup A isolates were also
more frequent than expected among bacteremic ESBL-producing
E. coli isolates in Spain (13). We hypothesize that previous antibi-
otic use would select for these less virulent (14), multidrug-resis-
tant strains, which hence may cause invasive infections in predis-
posed patients. IRT-producing strains were also associated with
UTI, but this was expected because they belonged predominantly
to phylogroup B2; finally, c-AmpC hyperproducers were also as-
sociated with bacteremic infections.
Our study has some limitations. We did not include a control
group formed by AMC-susceptible isolates. Outcome data were
not collected. Finally, the epidemiology of AMC-resistant E. coli
might be different in other areas. Some strengths of our work
include the multicenter nature and the combined analysis of mo-
lecular and clinical data.
In conclusion, AMC resistance in E. coli is a heterogeneous and
complex phenomenon of clinical importance. More studies are
needed to elucidate the importance of drivers potentially impli-
cated in the recent increase in the rate of resistance to AMC.
ACKNOWLEDGMENTS
Jesús Rodríguez-Baño has been a consultant for Wyeth, Merck, and Pfizer;
has served as a speaker for Wyeth, Merck, Pfizer, Astra-Zeneca, and
GlaxoSmithKline; and has received research support from Merck and
Wyeth. Alvaro Pascual has been a consultant for Merck and Pfizer; has
served as a speaker for Wyeth, Astra-Zeneca, Merck, and Pfizer; and has
received research support from Merck, Pfizer, and Wyeth. Germán Bou
has served as a speaker for Pfizer and Novartis and has received research
support from Pfizer. Luis Martínez-Martínez has been a consultant for
Wyeth and Pfizer; has served as a speaker for Wyeth, Merck, Pfizer, and
Janssen-Cilag; and has received research support from Merck, Wyeth, and
Janssen-Cilag. All other authors had no conflict of interest.
This study was supported by the Ministerio de Ciencia e Innovación,
Instituto de Salud Carlos III, cofinanced by the European Development
Regional Fund, A Way To Achieve Europe, ERDF; the Spanish Network
for the Research in Infectious Diseases (REIPI RD12/0015); the Fondo de
Investigación Sanitaria (grants PI08/0397, PI09/917, PI09/01702, 10/
02021, and 10/01955); and the Junta de Andalucía (grant CTS-5259).
REFERENCES
1. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project
Group. 2005. Outpatient antibiotic use in Europe and association with
resistance: a cross-national database study. Lancet 365:579 –587.
2. Campos J, Ferech M, Lázaro E, de Abajo F, Oteo J, Stephens P,
Goossens H. 2007. Surveillance of outpatient antibiotic consumption in
Spain according to sales data and reimbursement data. J. Antimicrob.
Chemother. 60:698 –701.
3. Oteo J, Campos J, Lázaro E, Cuevas O, García-Cobos S, Pérez-Vázquez
M, de Abajo FJ, Spanish Members of EARSS. 2008. Increased amoxicil-
lin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.
Emerg. Infect. Dis. 14:1259 –1262.
4. Blaettler L, Mertz D, Frei R, Elzi L, Widmer AF, Battegay M, Flückiger
U. 2009. Secular trends and risk factors for antimicrobial resistance in
Escherichia coli in Switzerland 1997-2007. Infection 37:534 –539.
5. Maraki S, Mantadakis E, Michailidis L, Samonis G. 11 July 2012. Chang-
ing antibiotic susceptibilities of community-acquired uropathogens in
Greece, 2005-2010. J. Microbiol. Immunol. Infect. [Epub ahead of print.]
doi:10.1016/j.jmii.2012.05.012.
6. Ortega A, Oteo J, Aranzamendi-Zaldumbide M, Bartolomé RM, Bou G,
Cercenado E, Conejo MC, González-López JJ, Marín M, Martínez-
Martínez L, Merino M, Navarro F, Oliver A, Pascual A, Rivera A,
Rodríguez-Baño J, Weber I, Aracil B, Campos J. 2012. Spanish multi-
center study of the epidemiology and mechanisms of amoxicillin-
clavulanate resistance in Escherichia coli. Antimicrob. Agents Chemother.
56:3576 –3581.
7. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada
JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C,
Llanos AC, Cantón R, Pascual A. 2008. Community infections caused by
extended-spectrum -lactamase-producing Escherichia coli. Arch. Intern.
Med. 168:1897–1902.
8. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance
definition of health care-associated infection and criteria for specific types
of infections in the acute care setting. Am. J. Infect. Control 36:309 –332.
9. Clinical and Laboratory Standards Institute. 2012. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed.
Approved standard M07-A9. Clinical and Laboratory Standards Institute,
Wayne, PA.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske
CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Pater-
son DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT,
Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and
pandrug-resistant bacteria: an international expert proposal for interim
standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:
268 –281.
TABLE 2 Types of infection caused by amoxicillin-clavulanate acid-resistant E. coli isolates according to mechanism of resistancea
Infection
% of patients (95% CI) harboring isolate with mechanism of resistance
All cases (n 212) HPen (n 54) IRT (n 43) c-AmpC (n 40) p-AmpC (n 40) OXA-1 (n 35)
Urinary tract 67 (60–73) 46 (34–59) 79 (65–88) 65 (49–78) 67 (52–80) 86 (71–94)
Asymptomatic bacteriuria 5 (3–10) 0 (0–7) 5 (1–15) 7 (2–20) 15 (7–29) 3 (0–14)
Cystitis 59 (53–66) 44 (32–58) 74 (60–85) 55 (40–69) 50 (35–65) 80 (64–90)
Pyelonephritis/prostatitis 2 (1–5) 2 (0–10) 0 (0–8) 2 (0–13) 2 (0–13) 3 (0–14)
Intra-abdominal infection 7 (4–12) 17 (9–29) 5 (1–15) 5 (1–16) 2 (0–13) 6 (1–19)
Skin and soft tissue infection 14 (10–19) 28 (18–41) 9 (4–21) 7 (2–20) 12 (5–26) 6 (1–19)
Respiratory tract infection 3 (1–6) 2 (0–10) 5 (1–15) 5 (1–16) 2 (0–13) 0 (0–10)
Primary bacteremia 4 (2–7) 2 (0–10) 0 (0–8) 10 (4–23) 5 (1–16) 3 (0–14)
Others 5 (3–9) 6 (2–15) 2 (0–12) 7 (2–20) 10 (4–23) 0 (0–10)
Bacteremia (primary or secondary) 7 (5–12) 6 (2–15) 2 (0–12) 15 (7–29) 5 (1–16) 11 (4–30)
a HPen, TEM-1 or SHV-1 hyperproducer; IRT, inhibitor-resistant TEM producer; c-AmpC, chromosomal AmpC hyperproducer; p-AmpC, plasmidic AmpC producer; OXA-1,
OXA-1 producer.
Rodríguez-Baño et al.
2416 jcm.asm.org Journal of Clinical Microbiology
 o
n
 January 29, 2016 by USE/BTCA.G
ENERAL UNIVERSITARIA Sevilla
http://jcm.asm.org/
D
ow
nloaded from
 
11. Rodríguez-Baño J, Miró E, Villar M, Coelho A, Gozalo M, Borrell N,
Bou G, Conejo MC, Pomar V, Aracil B, Larrosa N, Agüero J, Oliver A,
Fernández A, Oteo J, Pascual A, Navarro F. 2012. Colonisation and
infection due to Enterobacteriaceae producing plasmid-mediated AmpC
-lactamases. J. Infect. 64:176 –183.
12. Paterson DL. 2004. “Collateral damage” from cephalosporin or quino-
lone antibiotic therapy. Clin. Infect. Dis. 38(Suppl 4):S341–S345. doi:10
.1086/382690.
13. Rodríguez-Baño J, Mingorance J, Fernández-Romero N, Serrano L,
López-Cerero L, Pascual A, ESBL-REIPI Group. 2012. Virulence profiles
of bacteremic extended-spectrum-lactamase-producingEscherichia coli:
association with epidemiological and clinical features. PLoS One
7:e44238. doi:10.1371/journal.pone.0044238.
14. Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bingen E, Elion
J, Denamur E. 1999. The link between phylogeny and virulence in Esch-
erichia coli extraintestinal infection. Infect. Immun. 67:546 –553.
Amoxicillin-Clavulanate-Resistant E. coli
July 2013 Volume 51 Number 7 jcm.asm.org 2417
 o
n
 January 29, 2016 by USE/BTCA.G
ENERAL UNIVERSITARIA Sevilla
http://jcm.asm.org/
D
ow
nloaded from
 
